Cargando…

Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer

BACKGROUND: The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC). METHODS: Protein expression of n...

Descripción completa

Detalles Bibliográficos
Autores principales: Myklebust, M P, Li, Z, Tran, T H, Rui, H, Knudsen, E S, Elsaleh, H, Fluge, Ø, Vonen, B, Myrvold, H E, Leh, S, Tveit, K M, Pestell, R G, Dahl, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493874/
https://www.ncbi.nlm.nih.gov/pubmed/23099809
http://dx.doi.org/10.1038/bjc.2012.463
_version_ 1782249342325751808
author Myklebust, M P
Li, Z
Tran, T H
Rui, H
Knudsen, E S
Elsaleh, H
Fluge, Ø
Vonen, B
Myrvold, H E
Leh, S
Tveit, K M
Pestell, R G
Dahl, O
author_facet Myklebust, M P
Li, Z
Tran, T H
Rui, H
Knudsen, E S
Elsaleh, H
Fluge, Ø
Vonen, B
Myrvold, H E
Leh, S
Tveit, K M
Pestell, R G
Dahl, O
author_sort Myklebust, M P
collection PubMed
description BACKGROUND: The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC). METHODS: Protein expression of nuclear cyclin D1a and D1b was assessed by immunohistochemistry in 335 CRC patients treated with surgery alone or with adjuvant therapy using 5-FU/LEV. The prognostic and predictive value of these two molecular markers and clinicopathological factors were evaluated statistically in univariate and multivariate survival analyses. RESULTS: Neither cyclin D1a nor D1b showed any prognostic value in CRC or colon cancer patients. However, high cyclin D1a predicted benefit from adjuvant therapy measured in 5-year relapse-free survival (RFS) and CRC-specific survival (CSS) compared to surgery alone in colon cancer (P=0.012 and P=0.038, respectively) and especially in colon cancer stage III patients (P=0.005 and P=0.019, respectively) in univariate analyses. An interaction between treatment group and cyclin D1a could be shown for RFS (P=0.004) and CSS (P=0.025) in multivariate analysis. CONCLUSION: Our study identifies high cyclin D1a protein expression as a positive predictive factor for the benefit of adjuvant 5-FU/LEV treatment in colon cancer, particularly in stage III colon cancer.
format Online
Article
Text
id pubmed-3493874
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-34938742013-11-06 Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer Myklebust, M P Li, Z Tran, T H Rui, H Knudsen, E S Elsaleh, H Fluge, Ø Vonen, B Myrvold, H E Leh, S Tveit, K M Pestell, R G Dahl, O Br J Cancer Clinical Study BACKGROUND: The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC). METHODS: Protein expression of nuclear cyclin D1a and D1b was assessed by immunohistochemistry in 335 CRC patients treated with surgery alone or with adjuvant therapy using 5-FU/LEV. The prognostic and predictive value of these two molecular markers and clinicopathological factors were evaluated statistically in univariate and multivariate survival analyses. RESULTS: Neither cyclin D1a nor D1b showed any prognostic value in CRC or colon cancer patients. However, high cyclin D1a predicted benefit from adjuvant therapy measured in 5-year relapse-free survival (RFS) and CRC-specific survival (CSS) compared to surgery alone in colon cancer (P=0.012 and P=0.038, respectively) and especially in colon cancer stage III patients (P=0.005 and P=0.019, respectively) in univariate analyses. An interaction between treatment group and cyclin D1a could be shown for RFS (P=0.004) and CSS (P=0.025) in multivariate analysis. CONCLUSION: Our study identifies high cyclin D1a protein expression as a positive predictive factor for the benefit of adjuvant 5-FU/LEV treatment in colon cancer, particularly in stage III colon cancer. Nature Publishing Group 2012-11-06 2012-10-25 /pmc/articles/PMC3493874/ /pubmed/23099809 http://dx.doi.org/10.1038/bjc.2012.463 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Myklebust, M P
Li, Z
Tran, T H
Rui, H
Knudsen, E S
Elsaleh, H
Fluge, Ø
Vonen, B
Myrvold, H E
Leh, S
Tveit, K M
Pestell, R G
Dahl, O
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
title Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
title_full Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
title_fullStr Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
title_full_unstemmed Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
title_short Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
title_sort expression of cyclin d1a and d1b as predictive factors for treatment response in colorectal cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493874/
https://www.ncbi.nlm.nih.gov/pubmed/23099809
http://dx.doi.org/10.1038/bjc.2012.463
work_keys_str_mv AT myklebustmp expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT liz expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT tranth expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT ruih expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT knudsenes expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT elsalehh expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT flugeø expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT vonenb expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT myrvoldhe expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT lehs expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT tveitkm expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT pestellrg expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer
AT dahlo expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer